A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Dose escalation or repetition will be governed by pre-specified safety and activity rules. Subjects will be confined on either days 1-3 and/or days 8-10. Follow-up visits are also required periodically through day 43. Study procedures involve taking blood samples for pharmacokinetic, pharmacodynamic, virologic, and safety assessments.
Epistemonikos ID: 53768ff0f09817700ab01f3bf5f156d61ef95df9
First added on: Mar 23, 2020